Amundi Reduces Position in Glaukos Co. (NYSE:GKOS)

Amundi decreased its holdings in Glaukos Co. (NYSE:GKOS) by 4.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 115,418 shares of the medical instruments supplier’s stock after selling 5,199 shares during the period. Amundi owned 0.21% of Glaukos worth $18,250,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of GKOS. IFP Advisors Inc bought a new position in Glaukos in the 4th quarter worth approximately $43,000. Asset Planning Inc bought a new position in shares of Glaukos in the fourth quarter worth $90,000. Harvest Fund Management Co. Ltd grew its position in shares of Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 860 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Glaukos in the fourth quarter valued at $153,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock valued at $164,000 after purchasing an additional 807 shares during the period. Institutional investors own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

GKOS has been the subject of a number of recent analyst reports. Stifel Nicolaus lifted their target price on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and upped their target price for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Stephens upgraded shares of Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Truist Financial boosted their price target on shares of Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, Morgan Stanley downgraded Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a research report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $163.25.

Glaukos Stock Down 6.4 %

Shares of GKOS opened at $96.69 on Friday. Glaukos Co. has a 1 year low of $84.08 and a 1 year high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The stock has a 50 day simple moving average of $142.90 and a two-hundred day simple moving average of $138.16. The firm has a market cap of $5.47 billion, a P/E ratio of -33.69 and a beta of 0.99.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The business had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. On average, analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insider Transactions at Glaukos

In related news, insider Tomas Navratil sold 3,416 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at $15,310,024.65. This trade represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,744 shares of company stock worth $2,504,131. Company insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.